Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Cox proportional analysis estimated ApoB-related risk of incident CHD over a median follow-up period of 12.5 years with adjustments for nonlipid CHD risk factors.
|
29370999 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease.
|
30779793 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Odds ratio (OR) for coronary heart disease (CHD)-defined as coronary death, myocardial infarction, or coronary revascularization-per 10-mg/dL lower concentration of ApoB-containing lipoproteins.
|
30694319 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the kinetics of Lp(a) and LDL apolipoprotein B-100 (apoB) particles in patients with elevated Lp(a) and coronary artery disease undergoing regular apheresis.
|
30447089 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Among 12 case-control studies, an APOB PTV was present in 0.038% of CHD cases as compared to 0.092% of controls.
|
30939045 |
2019 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We investigated the association between plasma lipids, apolipoproteins levels, apolipoprotein B/low-density lipoprotein cholesterol (Apo-B/LDL-C), and Apo-B/Apo-A ratios and rate of cognitive decline two decades later in men with coronary heart disease (CHD).
|
30664505 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Individuals identified at metabolic risk should undergo 10-year global risk assessment for ASCVD or coronary heart disease to determine targets of therapy for reduction of apolipoprotein B-containing lipoproteins.
|
31365087 |
2019 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
While exposing the polygenic architecture of circulating lipids and the underpinnings of dyslipidaemia, these genome-wide association studies (GWAS) have provided further evidence of the critical role that lipids play in coronary heart disease (CHD) risk, as indicated by the 2.7-fold enrichment for macrophage gene expression in atherosclerotic plaques and the association of 25 loci (such as PCSK9, APOB, ABCG5-G8, KCNK5, LPL, HMGCR, NPC1L1, CETP, TRIB1, ABO, PMAIP1-MC4R, and LDLR) with CHD.
|
29800275 |
2018 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The combination of a portfolio dietary pattern and NCEP Step II diet significantly reduced the primary outcome LDL-C by ~17% (MD, -0.73 mmol/L, [95% CI, -0.89 to -0.56 mmol/L]) as well as non-high-density lipoprotein cholesterol, apolipoprotein B, total cholesterol, triglycerides, systolic and diastolic blood pressure, C-reactive protein, and estimated 10-year coronary heart disease (CHD) risk, compared with an NCEP Step 2 diet alone (p < 0.05).
|
29807048 |
2018 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ApoA-I levels were associated with higher levels of CHD risk factors: higher body mass index, HbA1c, non-HDL-C, triglycerides, apolipoprotein B, systolic blood pressure, and C-reactive protein, within fixed HDL-C quartiles.
|
28775061 |
2017 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In external validation analyses, a genetic score consisting of variants with naturally occurring discordance between levels of LDL-C and apoB was associated with a similar risk of CHD per unit change in apoB level (OR, 0.782 [95% CI, 0.720-0.845] vs 0.793 [95% CI, 0.774-0.812]; P = .79 for difference), but a significantly attenuated risk of CHD per unit change in LDL-C level (OR, 0.916 [95% CI, 0.890-0.943] vs 0.831 [95% CI, 0.816-0.847]; P < .001) compared with a genetic score associated with concordant changes in levels of LDL-C and apoB.
|
28846118 |
2017 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) and the Apolipoprotein B/A1 Ratio Independently Associate With Surgery for Aortic Stenosis Only in Patients With Concomitant Coronary Artery Disease.
|
29246959 |
2017 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our equation to predict apoB levels showed MCVE risk prediction comparable to directly-measured apoB in high risk patients with previous coronary heart disease.
|
28830468 |
2017 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to evaluate the effect of HDL-C, triglyceride, and apoB levels on the risk of coronary heart disease (CHD) in a Chinese population undergoing coronary angiography.
|
28506386 |
2017 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Fasting apoB-48 levels also correlate with carotid intima-media thickening and CHD prevalence, and a high apoB-48 level is a significant predictor of CHD risk, independent of the fasting TG level.
|
27829582 |
2017 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Postprandial triglycerides, TG-rich lipoprotein triglycerides, retinyl palmitate and apolipoprotein B48 to B100 ratio were measured before (following a 12-hour fasting period) and after a fat-tolerance test meal in a middle-aged, biracial subcohort without CVD (coronary heart disease (CHD) or stroke) from the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990-1993.
|
28191321 |
2017 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non-HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD).
|
28174174 |
2017 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Total effects of self-reported family history and a 50-variant GRS (GRS50), as well as effects mediated by apolipoprotein B and A-I (apoB, apoA-I), blood pressure, and diabetes mellitus, on incidence of CHD were estimated in 23 595 participants of the Malmö Diet and Cancer study (a prospective, population-based study).
|
28320750 |
2017 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease : A meta-analysis.
|
27637205 |
2016 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II.
|
27112212 |
2016 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the cumulative effect of high CRP level and apolipoprotein B-to-apolipoprotein A-1 (ApoB/ApoA-1) ratio on the incidence of ischemic stroke (IS) or coronary heart disease (CHD) in a Mongolian population in China.
|
27554116 |
2016 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis indicated that ApoB XbaI allele confers a significant risk towards the development of CHD among the Han Chinese population.
|
27172140 |
2016 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gene variants leading to higher levels of plasma apolipoprotein B-containing lipoproteins [low-density lipoprotein, triglyceride-rich lipoproteins, or lipoprotein(a)] consistently increase risk for CHD.
|
26892959 |
2016 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, we did not find association between apoB XbaI polymorphism and CHD.
|
26537298 |
2015 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor.
|
25070550 |
2014 |